TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Regencell Bioscience ( (RGC) ) is now available.
On June 17, 2025, Regencell Bioscience Holdings Limited announced the effectuation of a 38-for-one forward stock split, initially declared on June 2, 2025. This stock split, issued as a stock bonus, does not alter the company’s name, CUSIP, or trading symbol, and requires no action from shareholders, as adjustments will be automatically reflected in brokerage accounts or through the company’s transfer agent for registered shareholders.
More about Regencell Bioscience
Regencell Bioscience Holdings Limited is an early-stage bioscience company focused on the research, development, and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically targeting Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company aims to become a market leader in natural and holistic treatments for neurological disorders globally.
Average Trading Volume: 7,761,408
Technical Sentiment Signal: Buy
Current Market Cap: $29.67B
For detailed information about RGC stock, go to TipRanks’ Stock Analysis page.